지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2013.1
- 수록면
- 229 - 231 (3page)
이용수
초록· 키워드
오류제보하기
Trastuzumab (Herceptin), a humanized monoclonal antibody,is a cancer drug developed to target the human epidermal receptor (HER) 2, which is overexpressed in some cancer cells. Cutaneous side effects, such as folliculitis, xerosis, and alopecia have not been reported with therapies targeting HER2, in spite of the frequent observances of such with the therapies targeting the epidermal growth factor receptor. We experienced a patient in whom psoriasis was triggered by the trastuzumab treatment for breast cancer. She was a 57-year-old woman with erythematous and scaly plaques occurring a few months after starting trastuzumab, with repeated aggravation after the re-administration of trastuzumab for the breast cancer. Histologic examination showed the typical features of psoriasis with parakeratosis,epidermal hyperplasia, elongation of the rete ridges, and a lymphocytic and polymorphonuclear cell infiltrate in the dermis. To the best of our knowledge, this is the first report of psoriasis triggered by trastuzumab treatment for breast cancer.
목차
등록된 정보가 없습니다.
참고문헌 (8)
참고문헌 신청
Arteaga C / 2003 / Targeting HER1/EGFR: a molecular approach to cancer therapy / Semin Oncol 30 (3 Suppl 7) : 3 ~ 14
Chang HR / 2010 / Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer / Cancer 116 : 2856 ~ 2867
De Potter IY / 2001 / Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation / Exp Cell Re
Garnock-Jones KP / 2010 / Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer / Drugs 70 :
Laux I / 2006 / Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies / Br J Cancer 94 : 85 ~ 92
Chang HR / 2010 / Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer / Cancer 116 : 2856 ~ 2867
De Potter IY / 2001 / Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation / Exp Cell Re
Garnock-Jones KP / 2010 / Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer / Drugs 70 :
Laux I / 2006 / Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies / Br J Cancer 94 : 85 ~ 92
이 논문의 저자 정보
최근 본 자료
댓글(0)
0